Will Novo's LEADER Trial Move GLP-1 To The Diabetes Front Line?

Novo Nordisk AS has an impressive victory with a benefit demonstrated in the LEADER cardiovascular outcomes study of its GLP-1 agonist Victoza (liraglutide) in high-risk type 2 diabetes, but the real test could be whether the magnitude of benefit is big enough to shift practice and expand use beyond the class's tiny base.